Prevalencia y factores genéticos responsables de la toxicidad farmacológica: una revisión de la literatura actual
DOI:
https://doi.org/10.61154/rucs.v9i2.4515Palabras clave:
epidemiología, farmacogenética, farmacovigilancia, polimorfismos, reacciones adversasResumen
La toxicidad farmacológica en la actualidad representa un desafío para el sistema de salud actual, donde los factores responsables se asocian en su mayoría con alteraciones genéticas. El objetivo de este estudio fue analizar la prevalencia y factores genéticos responsables de la toxicidad farmacológica mediante una revisión sistemática documental de tipo descriptivo en base a las directrices establecidas por la guía PRISMA 2020. De 1.542 documentos, solo se utilizaron 53 artículos mediante criterios de elegibilidad. Los resultados mostraron que Turquía (64.9%) y Uganda, África (61.8%) presentan las prevalencias más altas en cuanto a la toxicidad farmacológica. Además, esta complicación se asocia directamente a factores genéticos como alteraciones en la actividad enzimática, provocando así toxicidad espontánea. Por último, el control periódico de medicamentos, la evaluación del historial farmacológico y el registro de las reacciones adversas fueron las recomendaciones más enfatizadas ante esta problemática. Se concluye que el monitoreo y evaluación mediante herramientas tecnológicas y guías validadas por organizaciones mundiales pueden mitigar el impacto de la toxicidad farmacológica.Descargas
Citas
Qahwaji S, Ashankyty V, Sannan S, Hazzazi S, Basabrain AA, Mobashir M. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals 2. 2024; 17(7): p. 940. https://doi.org/10.3390/ph17070940.
Haag D, Bellamkonda R, Perinpam B, Peters J, Sunga L, Gross L, et al. Prevalence and Categorization of Drug-Related Problems in the Emergency Department. J Emerg Med. 2022; 63(2): p. 192-199. https://doi.org/10.1016/j.jemermed.2022.04.016.
Komagamine J. Prevalence of urgent hospitalizations caused by adverse drug reactions: a cross-sectional study. Sci Rep. 2024; 14(1): p. 6058. https://doi.org/10.1038/s41598-024-56855-z.
Chiarella R, Capone G, Sisto B. Contribution of Genetic Polymorphisms in Human Health. Int. J. Environ. Res. Public Health. 2023; 20(2): p. 912. https://doi.org/10.3390/ijerph20020912.
Egwu O, Aloke N, Onwe T, Umoke I, Nwafor G, Eyo A, et al. Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine. Molecules. 2024; 29(11): p. 2584. https://doi.org/10.3390/molecules29112584.
Javor T, Hauser G, Skelin S. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases. JAMA. 2022; 327(15): p. 1505-1506. https://doi.org/10.1001/jama.2022.2935.
GBD 2023 Lower Respiratory Infections and Antimicr. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis. 2025; 15: p. S1473-3099(25)00689-9. https://doi.org/10.1016/s1473-3099(25)00689-9.
Gupta F, Rajpoot F, Tekade M, Sharma B, Safavi M, Tekade J. Chapter 2 - Factors influencing drug toxicity. Pharmacokinetics and Toxicokinetic Considerations. 2022; 2:27-50. https://doi.org/10.1016/B978-0-323-98367-9.00014-7.
Panchal NK, Sabina E. Non-steroidal anti-inflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities. Food and Chemical Toxicology. 2023; 172: p. 113598. https://doi.org/10.1016/j.fct.2022.113598.
Xuan T, Ju Z, Skonieczna H, Zhou PK, Huang R. Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. MedComm. 2023; 4(4): p. e327. https://doi.org/10.1002/mco2.327.
Alhamadani F, Zhang V, Parikh J, Wu M, Rasmussen P, Bahal U, et al. Adverse Drug Reactions and Toxicity of the Food and Drug Administration–Approved Antisense Oligonucleotide Drugs. Drug Metabolism and Disposition. 2022; 50(6): p. 879-887. https://doi.org/10.1124/dmd.121.000418.
Sakiris MA, Hilmer N, Sawan J, Lo O, Kelly J, Blyth M, et al. Prevalence of Adverse Drug Reactions in Hospital Among Older Patients with and Without Dementia. Drugs Aging. 2024; 41(10): p. 833-846. https://doi.org/10.1007/s40266-024-01148-3.
Martínez N, Villa-Dangond S, López M, Guzmán A. Adverse Drug Events Presented in Health Institutions in Monteria, Colombia, 2018–2021. Journal of Multidisciplinary Healthcare. 2023; 16: p. 3887–3895. https://doi.org/10.2147/JMDH.S426626.
Yacelga-Gómez JJ, Valenzuela-Madera AJ, Chicaiza-Montero F, Medina-León A, Cargua-Usca M. Automedicación con antibióticos en Ecuador y Latinoamérica: magnitud, determinantes y propuestas de intervención. Revista Científica Ciencia Y Método. 2025; 3(4): p. 14-23. https://doi.org/10.55813/gaea/rcym/v3/n4/94.
Torres Ramírez F, Vera Cedeño M. Factores socioculturales y educativos que influyen en el uso inadecuado de antibióticos en la población ecuatoriana. Ciencia Ecuador. 2025; 7(32): p. 50-61. https://doi.org/10.69825/cienec.v7i32.348.
Page J, McKenzie E, Bossuyt PM, Boutron G, Hoffmann C, Mulrow D, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021; 74(9): p. 790-799. https://doi.org/10.1016/j.rec.2021.07.010.
Hirsch B, Giesler M, Matthes M, Homberg L, Himmelbauer I, Bauer O, et al. Developing recommendations on ethical aspects affecting studies in health professions education research. GMS J Med Educ. 2026; 43(1): p. Doc1. https://doi.org/10.3205/zma001795.
Georgiev D, Hvarchanova G, Stoychev E, Kanazirev. Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics. Sci Prog. 2022; 105(1): p. 368504211070183. https://doi.org/10.1177/00368504211070183.
Brown NJ, Doran N, Greenslade H, Lukin L, Cottrell O, Jaramillo A, et al. Retrospective study of the prevalence and characteristics of adverse drug events in adults who present to an Australian emergency department. Emerg Med Australas. 2022; 34(4): p. 547-554. https://doi.org/10.1111/1742-6723.13929.
Aksoy V, Ozturk N. A meta-analysis assessing the prevalence of drug-drug interactions among hospitalized patients. Pharmacoepidemiol Drug Saf. 2023; 32(12): p. 1319-1330. https://doi.org/10.1002/pds.5691.
Brandariz-Núñez D, Ferreiro-Gómez B, Suanzes J, Margusino-Framiñán M, Cámara-Gómez Mdl, Fandiño-Orgueira M, et al. Prevalence of adverse drug reactions associated with emergency department visits and risk factors for hospitalization. Farm Hosp. 2023; 47(1): p. T20-T25. https://doi.org/10.1016/j.farma.2022.12.007.
Babirye G, Yadesa Y, Tamukong B. Prevalence and factors associated with drug therapy problems among hypertensive patients at hypertension clinic of Mbarara Regional Referral Hospital, Uganda: a |cross-sectional study. Ther Adv Cardiovasc Dis. 2023; 17: p. 17539447231160319. https://doi.org/10.1177/17539447231160319.
Camargo C, Matte H, Botton R. Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil. Expert Opin Drug Saf. 2023; 22(7): p. 621-627. https://doi.org/10.1080/14740338.2023.2181337.
Ramasubbu K, Mishra A, Mandal V. Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis. J Pharm Pract. 2024; 37(1): p. 162-168. https://doi.org/10.1177/08971900221121371.
Hodel D, De Min B, Thorball U, Redin K, Vollenweider V, Girardin M, et al. Prevalence of actionable pharmacogenetic variants and high-risk drug prescriptions: A Swiss hospital-based cohort study. Clin Transl Sci. 2024; 17(9): p. e70009. https://doi.org/10.1111/cts.70009.
Insani N, Whittlesea T, Wei. Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: A cross-sectional study. PLoS One. 2024; 19(7): p. e0307237. https://doi.org/10.1371/journal.pone.0307237.
Reich LA, Daiello LA, Berry SD, D'Amico AM, Kiel DP, Harris DA, Hayes KN, Leonard CE, Hsu YS, Zullo AR. Prevalence and Duration of Potential Drug-Drug Interactions Among US Nursing Home Residents, 2018-2020. J Am Geriatr Soc. 2025; 73(12): p. 3766-3777. https://doi.org/10.1111/jgs.70175.
Zhao F, Zhang Z, Wang S, Hong Y, Zhou X, Zhou R, et al. Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population. Front. Pharmacol. 2022; 13: p. 1007268. https://doi.org/10.3389/fphar.2022.1007268.
Casajús G, Zubiaur P, Méndez B, Campodónico O, Gómez N, Navares-Gómez O, et al. Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers. Advances in Therapy. 2022; 39: p. 1743–1753. https://doi.org/10.1007/s12325-022-02067-8.
Li R, Chen T, Jie F, Xiang H, Huang K, Jiang H, et al. Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement. Medicine. 2022; 101(29):e29626. https://doi.org/10.1097/MD.0000000000029626.
De Mattia B, Silvestri K, Polesel J, Ecca F, Mezzalira O, Scarabel B, et al. Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk. Biomedicine & Pharmacotherapy. 2022; 154:113644. https://doi.org/10.1016/j.biopha.2022.113644.
Membrive-Jiménez C, Vieira-Maroun T, Márquez-Pete N, Cura H, Pérez-Ramírez M, Tercedor-Sánchez J, et al. ABCC1, ABCG2 and FOXP3: Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis. Biomedicines. 2023; 11(9):2567. https://doi.org/10.3390/biomedicines11092567.
Shubbar Q, Alchakee A, Walid K, Adi G, Shorbagi M, Saber-Ayad. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Front. Pharmacol. 2024; 15:1326776. https://doi.org/10.3389/fphar.2024.1326776.
Gündüz A, Duman D, Başbinar Y, Taşdelen B, Küpeli S, Karpuz D. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors. Journal of Pediatric Hematology/Oncology. 2024; 46(1):e65-e70. https://doi.org/10.1097/MPH.0000000000002768.
Johansson I, Xanthopoulou M, Zhou Y, Sanchez-Spitman B, van der Lee E, Wollmann M, et al. Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account. Clinical Pharmacology & Therapeutics. 2025; 118(1):218-231. https://doi.org/10.1002/cpt.3680.
Magadmi A, Alharthi M, Alqurashi A, Jali M, Sharawi W, Jamal H, et al. Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients. Pharmaceuticals. 2025; 18(7):1069. https://doi.org/10.3390/ph18071069.
Jittikoon J, Saengsiwaritt W, Chanhom J, Chaikledkaew U, Wattanapokayakit , Mahasirimongkol V, et al. Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential. Scientific Reports. 2025; 15:10197. https://doi.org/10.1038/s41598-025-95050-6.
Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022; 7(2):100404. https://doi.org/10.1016/j.esmoop.2022.100404.
Ahmad K, Imran N, Sharma T. Precision Nanotoxicology in Drug Development: Current Trends and Challenges in Safety and Toxicity Implications of Customized Multifunctional Nanocarriers for Drug-Delivery Applications. Pharmaceutics. 2022; 14(11):2463. https://doi.org/10.3390/pharmaceutics14112463.
Ioele E, Chieffallo R, Occhiuzzi A, De Luca H, Garofalo L, Ragno M, et al. Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. Molecules. 2022; 27(17):5436. https://doi.org/10.3390/molecules27175436.
Yen NTH, Park SM, Thu VTA, Phat NK, Cho YS, Yoon S, et al. Genome-wide gene expression analysis reveals molecular insights into the drug-induced toxicity of nephrotoxic agents. Life Sci. 2022;306:120801. doi:10.1016/j.lfs.2022.120801.
Ambrosioni N, Levi L, Alagaratnam L, Van Bremen K, Mastrangelo O, Waalewijn R, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Medicine. 2023; 24(11): p. 1126-1136. https://doi.org/10.1111/hiv.13542.
Mazumdar V, Sarma KD, Mahanta T. Predicting Renal Toxicity of Compounds with Deep Learning and Machine Learning Methods. SN Computer Science. 2023; 4: p. 812. https://doi.org/10.1007/s42979-023-02258-2.
Ishiguro T, Takahash V, Arakaw N, Saito M, Kitagawa F, Kondo O, et al. Improvement of Protein Expression Profile in Three-Dimensional Renal Proximal Tubular Epithelial Cell Spheroids Selected Based on OAT1 Gene Expression: A Potential In Vitro Tool for Evaluating Human Renal Proximal Tubular Toxicity and Drug Disposition. Drug Metabolism and Disposition. 2023; 51(9): p. 1177-1187. https://doi.org/10.1124/dmd.122.001171.
Liu D, Wang X, Xu Z, Yan T, Zha J, Wang N, et al. Antiepileptic drugs in aquatic environments: Occurrence, toxicity, transformation mechanisms and fate. Critical Reviews in Environmental Science and Technology. 2023; 53: p. 2030-2054. https://doi.org/10.1080/10643389.2023.2209010.
Myung T, de Sá GC, Ascher DB. Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic Acids Research. 2024; 52: p. W469–W475. https://doi.org/10.1093/nar/gkae254.
Abbas S, Liang F, Chen B, Qu U, Khan, ,I Ashaq M, et al. Toxicity Challenges and Current Advancement in Metal–Organic Frameworks (MOFs) for Biomedical Applications. Biological Trace Element Research. 2026; 204: p. 836–852. https://doi.org/10.1007/s12011-025-04712-z.
Xiao O, Song D, Huang S, Hou Z, Huang X. Global prevalence and characteristics of non-suicidal self-injury between 2010 and 2021 among a non-clinical sample of adolescents: A meta-analysis. Front. Psychiatry. 2022; 13: p. 912441. https://doi.org/10.3389/fpsyt.2022.912441.
Omotoso R, Olashore A, Sempa B, Alaofin S, Dheda M, Tabane N, et al. The prevalence of adverse drug reactions to antiretroviral therapy and associated factors among pediatric patients living with HIV in sub-Saharan African countries: a systematic review and meta-analysis. BMC Infect Dis. 2025; 25(1): p. 1782. https://doi.org/10.1186/s12879-025-12107-7.
Chiwambutsa M, Ayeni U, Kapungu I, Kanji, C, Thelingwani O, Chen C, et al. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer. Clinical Pharmacology & Therapeutics. 2023; 114(1): p. 127-136. https://doi.org/10.1002/cpt.2904.
Tan T, Han G, Cheng Z, Jiang J, Zhang L, Xia O, et al. Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer. Front. Pharmacol. 2022; 13: p. 918219. https://doi.org/10.3389/fphar.2022.918219.
Palis L, Hu M, Tu A, Scheuermeyer T, Staples A, Moe J, et al. Chronic disease diagnoses and health service use among people who died of illicit drug toxicity in British Columbia, Canada. BMC Medicine. 2024; 22: p. 479. ttps://doi.org/10.1186/s12916-024-03646-y.
Yang F, Kar S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. Artificial Intelligence Chemistry. 2023; 1(2): p. 100011. https://doi.org/10.1016/j.aichem.2023.100011.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 David Demera Chica, Jennifer Analhy Pacha Venegas, Fernando Isaías Cedeño Valdiviezo, María Lillly Parraga Sanchez
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
Se recomienda a los autores publicar su trabajo en Internet (por ejemplo en páginas institucionales o personales) en la versión final publicada por Revista UNIANDES de Ciencias de la Salud, ya que puede conducir a una mayor y más rápida difusión del trabajo publicado (vea The Effect of Open Access).
OAI-PMH URL: https://revista.uniandes.edu.ec/ojs/index.php/RUCSALUD/oai
